ETF Holdings Breakdown of VERV

News associated with VERV

Jefferies Financial Group Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

Verve Therapeutics (NASDAQ:VERV – Get Free Report) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report released on Wednesday, Marketbeat.com reports. They currently have a $11.00 price objective on the stock, down from their prior price objective of $28.00. Jefferies Financial Group’s target price […] - 2025-06-20 05:56:52

Verve Therapeutics Target of Unusually High Options Trading (NASDAQ:VERV)

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 51,590 put options on the company. This represents an increase of 8,413% compared to the typical daily volume of 606 put options. Institutional Trading of Verve Therapeutics Institutional investors and hedge funds have […] - 2025-06-19 05:54:58

Verve Therapeutics (NASDAQ:VERV) Rating Lowered to Hold at Canaccord Genuity Group

Verve Therapeutics (NASDAQ:VERV – Get Free Report) was downgraded by analysts at Canaccord Genuity Group from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a $13.00 price target on the stock, down from their previous price target of $39.00. Canaccord Genuity Group’s price target […] - 2025-06-19 05:18:51

Harbor Capital Advisors Inc. Reduces Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Harbor Capital Advisors Inc. reduced its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 30.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,976 shares of the company’s stock after selling 12,568 shares during the quarter. Harbor Capital […] - 2025-06-16 07:46:53

Verve Therapeutics, Inc. (NASDAQ:VERV) Receives Average Rating of “Buy” from Analysts

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in […] - 2025-06-13 05:55:10

Public Employees Retirement System of Ohio Raises Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Public Employees Retirement System of Ohio grew its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 81.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 106,356 shares of the company’s stock after purchasing an additional 47,656 shares during the […] - 2025-06-05 08:10:51

ProShare Advisors LLC Acquires 5,592 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

ProShare Advisors LLC increased its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 30.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 24,016 shares of the company’s stock after acquiring an additional 5,592 shares during the period. ProShare Advisors LLC’s […] - 2025-06-03 07:50:51

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP increased its position in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 32.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 570,304 shares of the company’s stock after acquiring an additional 140,030 shares during the period. Two Sigma […] - 2025-05-30 09:40:48

Two Sigma Advisers LP Has $1.65 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Two Sigma Advisers LP grew its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 58.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 293,200 shares of the company’s stock after buying an additional 108,600 shares during the period. Two Sigma Advisers LP owned […] - 2025-05-30 08:34:51

D. E. Shaw & Co. Inc. Purchases New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

D. E. Shaw & Co. Inc. bought a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) during the fourth quarter, Holdings Channel.com reports. The firm bought 37,984 shares of the company’s stock, valued at approximately $214,000. A number of other hedge funds and other institutional investors have also recently made changes […] - 2025-05-29 07:36:54

Millennium Management LLC Cuts Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Millennium Management LLC lowered its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 22.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,919,131 shares of the company’s stock after selling 1,105,050 shares during the quarter. Millennium Management LLC’s holdings in […] - 2025-05-21 08:04:54

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of “Buy” by Analysts

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock […] - 2025-05-19 05:48:46

Dimensional Fund Advisors LP Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Dimensional Fund Advisors LP boosted its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 1.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,089 shares of the company’s stock after purchasing an additional 5,320 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Verve Therapeutics were worth $2,465,000 […] - 2025-05-15 07:31:10

Invesco Ltd. Buys 3,080 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Invesco Ltd. raised its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 5.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 57,140 shares of the company’s stock after purchasing an additional 3,080 shares during the period. Invesco Ltd.’s holdings in Verve Therapeutics were worth $322,000 as of its most recent […] - 2025-05-05 07:38:47

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next. Even so, Wall Street has high hopes for some companies. Take Verve Therapeutics - 2025-04-29 11:53:00

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Bank of Montreal Can

Bank of Montreal Can trimmed its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 12.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,139 shares of the company’s stock after selling 6,131 shares during the quarter. Bank of Montreal Can owned about […] - 2025-04-25 07:36:51

Geode Capital Management LLC Increases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Geode Capital Management LLC increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,625,780 shares of the company’s stock after buying an additional 25,093 shares during the quarter. […] - 2025-04-24 07:58:47

Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $25.75 Average Price Target from Brokerages

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the […] - 2025-04-22 05:18:51

Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $24.00

Verve Therapeutics (NASDAQ:VERV – Free Report) had its price objective increased by Guggenheim from $18.00 to $24.00 in a research report sent to investors on Tuesday morning, Marketbeat reports. Guggenheim currently has a buy rating on the stock. Other research analysts have also recently issued reports about the stock. William Blair reaffirmed an “outperform” rating […] - 2025-04-18 07:43:01

Verve Therapeutics (NASDAQ:VERV) Upgraded to Overweight at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Verve Therapeutics (NASDAQ:VERV – Free Report) from a neutral rating to an overweight rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. VERV has been the topic of several other research reports. Royal Bank of Canada lowered their price objective on Verve Therapeutics from $17.00 to […] - 2025-04-16 07:48:54

Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $39.00 at Canaccord Genuity Group

Verve Therapeutics (NASDAQ:VERV – Free Report) had its target price upped by Canaccord Genuity Group from $32.00 to $39.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on VERV. HC Wainwright upped their price target on […] - 2025-04-16 07:48:52

Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $25.00 at HC Wainwright

Verve Therapeutics (NASDAQ:VERV – Get Free Report) had its price objective raised by HC Wainwright from $15.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 403.02% from the company’s previous close. VERV has been […] - 2025-04-16 05:34:51

Pre-Market Most Active for Apr 14, 2025 : TSLL, KIDZ, NVDA, TQQQ, VERV, SQQQ, NIO, PFE, BABA, PG, DELL, TSM

The NASDAQ 100 Pre-Market Indicator is up 343.25 to 19,033.3. The total Pre-Market volume is currently 389,799,187 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.35 at $8.76, with 14,127,863 shar - 2025-04-14 12:29:57

KLP Kapitalforvaltning AS Buys Shares of 17,900 Verve Therapeutics, Inc. (NASDAQ:VERV)

KLP Kapitalforvaltning AS purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 17,900 shares of the company’s stock, valued at approximately $101,000. Other large investors also recently modified their holdings of the […] - 2025-04-11 08:39:05

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 2,742 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 5.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,230 shares of the company’s stock after buying an additional 2,742 shares during the […] - 2025-04-04 08:12:55

Teacher Retirement System of Texas Has $114,000 Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Teacher Retirement System of Texas lifted its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 37.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 20,254 shares of the company’s stock after acquiring an additional 5,512 shares during the quarter. Teacher […] - 2025-04-03 07:16:48

Verve Therapeutics (NASDAQ:VERV) Earns Buy Rating from HC Wainwright

Verve Therapeutics (NASDAQ:VERV – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 177.78% from the company’s previous close. Several other research […] - 2025-03-27 06:00:57

Guggenheim Reaffirms “Buy” Rating for Verve Therapeutics (NASDAQ:VERV)

Guggenheim restated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a report published on Tuesday,Benzinga reports. A number of other research analysts have also recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC […] - 2025-03-26 06:52:43

Bank of New York Mellon Corp Grows Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Bank of New York Mellon Corp increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 2.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 220,502 shares of the company’s stock after acquiring an additional 5,262 shares during the quarter. Bank of New York Mellon Corp’s holdings in Verve Therapeutics […] - 2025-03-24 07:10:51

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down Following Analyst Downgrade

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report)’s share price gapped down prior to trading on Tuesday after Royal Bank of Canada lowered their price target on the stock from $17.00 to $15.00. The stock had previously closed at $6.17, but opened at $5.86. Royal Bank of Canada currently has an outperform rating on the […] - 2025-03-06 08:13:40

VERV institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	59,364	USD 668,142
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	60,605	USD 682,109
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	44,131	USD 496,694
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	44,131	USD 496,694
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	5,543	USD 62,386
Total =		213,774	USD 2,406,025

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer